81 results
8-K
EX-10.1
ARAV
Aravive Inc
17 Jan 24
Entry into a Material Definitive Agreement
4:22pm
to economic loss, property damage, personal injury or death in connection with, or occurring on or in the vicinity of, any assets of the assignment
8-K
EX-10.2
ARAV
Aravive Inc
11 Apr 23
Aravive Appoints Carolina Petrini as Chief Commercial Officer
7:10am
of your Continuous Service for any reason other than Cause, Disability, or death;
(c) 12 months after the termination of your Continuous Service due … to your Disability;
(d) 18 months after your death if you die during your Continuous Service;
(e) immediately upon a Corporate Transaction
8-K
EX-10.2
ARAV
Aravive Inc
26 Oct 22
Aravive Announces Approximately $41.5 Million Private Placement Financing
4:35pm
or ceases to be a director (whether as a result of his or her death, disability, disqualification, or otherwise) the Investors shall be entitled
8-K
pb8ek2ca5m8df 9w6j
4 Jan 22
Entry into a Material Definitive Agreement
6:02am
8-K
EX-10.1
blpf cdgd
4 Jan 22
Entry into a Material Definitive Agreement
6:02am
8-K
EX-99.1
t9s gki6tifozm4yrx
9 Aug 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
7:09am
8-K
EX-10.1
2dqgkag8
14 Jun 21
Entry into a Material Definitive Agreement
4:08pm
8-K
u5s9kc 80
18 May 21
Aravive Announces Three New Appointments to its Board of Directors
7:05am
8-K
EX-99.2
nkrhx e97vrr7x80hv
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.1
hbu30rl9
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.2
ddn30o eo8xm5wqibdap
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
zmwr26
8 Mar 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
7:05am